Norethindron-13C2

Norethindrone-13C2 (Norethisterone-13C2) is 13C labeled Norethindrone. Norethindrone is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea.

201741-02-8

Norethisterone-13C2

12352211

Bacterial; Isotope-Labeled Compounds; Progesterone Receptor

Anti-infection; Others; Vitamin D Related/Nuclear Receptor

Endocrinology; Cancer

10 mM in DMSO

C[C@@]12[C@](CC[C@@]2(O)[13C]#[13CH])([H])[C@@]3([H])[C@]([C@]4([H])C(CC3)=CC(CC4)=O)([H])CC1

C18 13C2H26O2

300.40

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Muneyyirci-Delale O, et al. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998 Jan-Feb;43 (1) :24-7.|[3]Kaser DJ, et al. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. J Pediatr Adolesc Gynecol. 2012 Apr;25 (2) :105-8.|[4]Maier WE, et al. Pharmacology and toxicology of ethinyl estradiol and norethindrone acetate in experimental animals. Regul Toxicol Pharmacol. 2001 Aug;34 (1) :53-61.|[5]Cheng DC, et al. Norethindrone acetate inhibition of triglyceride synthesis and release by rat hepatocytes. Atherosclerosis. 1983 Jan;46 (1) :41-8.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-B0554S1/

Isotope-Labeled Compounds

No Development Reported